Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...
The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...
The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...
The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...
The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...
Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies ...
The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin ...
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...
Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback